Hans-Peter Fischer

Alta Partners Management Co. LP (Alta Partners) is a venture capital firm founded in 1996 by Jean Deleage, Guy Paul Nohra, Marino Polestra and Garrett P. Gruener. The firm is headquartered in Jackson, Wyoming.

Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY.

Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA.

Supranational

PamGene is a biomarker company, focused on opening up new opportunities for the development of Personalized Medicine (pre-clinical, translational and clinical). Most of PamGene's projects are in oncology and many of these involve medicines that inhibit or modulate cellular kinases and kinase pathways. The firm collaborators apply its technologies for biomarker research in several other diseases and fields of expertise such as the Central Nervous System, the Cardiovascular area, Immunology and Obesity. PamGene's technology offers a faster and lower risk route for discovery and development of clinically useful biomarkers and uses cell lines and retrospective patient sample collection testing.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands.

7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark.

The Society for Laboratory Automation & Screening (SLAS) sets standards for microplate development through its Microplate Standards Advisory Committee. The non-profit company is based in St. Charles, IL. SLAS offers various platforms for education, scientific publishing, collaboration, networking, and career advancement for its international community. The company has developed a new micro-credentials program exclusively for the life sciences industry. SLAS's mission is to connect laboratory technology providers with laboratory technology users.